Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA) has granted inducement awards to five new employees as announced by the Compensation Committee of its Board of Directors on December 20, 2024. The awards include options to purchase 100,000 shares of common stock at $3.23 per share and restricted stock units (RSUs) covering 100,000 shares.
The equity awards were granted under Savara's 2021 Inducement Equity Incentive Plan per NASDAQ Rule 5635(c)(4). The options have a 10-year term with quarterly vesting of 1/16th of shares, while RSUs fully vest after two years, both subject to continued employment.
Savara Inc. (Nasdaq: SVRA) ha conferito premi di incentivazione a cinque nuovi dipendenti, come annunciato dal Comitato per la Compensazione del Consiglio di Amministrazione il 20 dicembre 2024. I premi includono opzioni per l'acquisto di 100.000 azioni di azioni ordinarie a $3,23 per azione e unità di azioni vincolate (RSU) che coprono 100.000 azioni.
Le attribuzioni azionarie sono state concesse nell'ambito del Piano di Incentivazione Azionaria per l'Induzione del 2021 di Savara, in conformità con la Regola NASDAQ 5635(c)(4). Le opzioni hanno un termine di 10 anni con acquisizione trimestrale di 1/16 delle azioni, mentre le RSU si acquisiscono completamente dopo due anni, entrambe soggette a un impiego continuato.
Savara Inc. (Nasdaq: SVRA) ha otorgado premios de inducción a cinco nuevos empleados, como anunció el Comité de Compensación de su Junta Directiva el 20 de diciembre de 2024. Los premios incluyen opciones para comprar 100,000 acciones de acciones ordinarias a $3.23 por acción y unidades de acciones restringidas (RSU) que cubren 100,000 acciones.
Los premios de capital se otorgaron bajo el Plan de Incentivos de Capital por Inducción de 2021 de Savara de acuerdo con la Regla NASDAQ 5635(c)(4). Las opciones tienen un plazo de 10 años con un vesting trimestral de 1/16 de las acciones, mientras que las RSU se adquieren completamente después de dos años, ambas sujetas a empleo continuo.
사바라 Inc. (Nasdaq: SVRA)는 2024년 12월 20일 이사회 보상위원회가 발표한 대로 다섯 명의 신규 직원에게 인센티브 상을 부여했습니다. 상에는 100,000주를 구매할 수 있는 옵션이 포함되어 있으며, 주당 $3.23에 일반주를 구매할 수 있고 100,000주를 포함하는 제한된 주식 단위(RSU)가 포함되어 있습니다.
주식 상은 사바라의 2021 인센티브 주식 계획에 따라 NASDAQ 규칙 5635(c)(4)에 따라 부여되었습니다. 옵션은 10년의 기간을 가지며, 매 분기 1/16주씩 수익이 발생하며, RSU는 2년 후 전체 수익이 발생합니다. 두 경우 모두 계속 고용 중이어야 합니다.
Savara Inc. (Nasdaq: SVRA) a accordé des primes d'incitation à cinq nouveaux employés, comme annoncé par le Comité de Compensation de son Conseil d'Administration le 20 décembre 2024. Les primes comprennent des options d'achat de 100 000 actions ordinaires au prix de 3,23 $ par action et des unités d'actions restreintes (RSU) couvrant 100 000 actions.
Les attributions d'actions ont été accordées dans le cadre du Plan d'Incitation d'Actions de 2021 de Savara conformément à la règle NASDAQ 5635(c)(4). Les options ont une durée de 10 ans avec un droit d'acquisition trimestriel de 1/16 des actions, tandis que les RSU sont complètement acquises après deux ans, toutes deux sous réserve d'un emploi continu.
Savara Inc. (Nasdaq: SVRA) hat fünf neuen Mitarbeitern Anreizprämien gewährt, wie vom Vergütungsausschuss des Vorstands am 20. Dezember 2024 bekannt gegeben. Die Prämien beinhalten Optionen zum Kauf von 100.000 Aktien zum Preis von 3,23 $ pro Aktie sowie eingeschränkte Aktieneinheiten (RSU), die 100.000 Aktien abdecken.
Die Aktienprämien wurden gemäß dem Anreiz-Aktienplan von Savara aus dem Jahr 2021 gemäß der NASDAQ-Regel 5635(c)(4) gewährt. Die Optionen haben eine Laufzeit von 10 Jahren mit vierteljährlicher Vesting von 1/16 der Aktien, während RSUs nach zwei Jahren vollständig vesting, beide unter der Voraussetzung, dass die Anstellung fortgesetzt wird.
- Expansion of workforce with five new strategic hires
- Implementation of employee retention strategy through equity incentives
- Potential dilution of existing shareholders through new equity grants of 200,000 shares
On December 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to five new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 100,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 100,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.
The options have an exercise price of
About Savara
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, X: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241223814372/en/
Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com
Source: Savara Inc.
FAQ
How many shares are included in SVRA's December 2024 inducement awards?
What is the exercise price for SVRA's new stock options granted in December 2024?
What is the vesting schedule for SVRA's December 2024 inducement RSUs?
How do the stock options vest in SVRA's December 2024 inducement grants?
